Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 59Observational 3Expanded_access 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Polycythemia Vera 2Primary Myelofibrosis 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × ruxolitinib × Clear all
NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Novartis

Available
Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT05269771 2025-11-05

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Novartis

No longer available
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡